Macau University of Science and Technology

Jing-Rong Wang

Zhi-Hong Jiang

Guo-Yuan Zhu

Liang Liu

Weina Gao

Cheng-Yu Chen

Hao Huang

Leefong Yau

Jia-Ning Mi

Qiong Meng

Tiantian Tong

Nanshan Zhong

Zifeng Yang

Wei-Na Gao

Junping Kou

Yuwei Han

Yingqiong Xu

Qi-Tong Feng

A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from, in particular from wild-type, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities. A method of treating a subject suffering from an inflammatory disease like an autoimmune disease or an allergic disease includes administering sphingolipids isolated from, in particular from wild-type. A method of treating a subject suffering from an inflammatory disease includes administering certain sphingolipids to the subject. Still further in accordance with the present invention is a composition, in particular a pharmaceutical composition comprising at least one sphingolipid portion.

Method of isolating sphingolipids from cordyceps and their use

The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

Use of glycan as biomarkers for autoimmune diseases

The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from

Method of isolating anti-viral ingredients from, compositions comprising them and their medical use

A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, fromis used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.

[object Object]

A method of identifying and preferably quantifying at least one sphingolipid, in particular the sphingolipid portion in wild-typeorderivates includes preparing a test sample solution from asample, subjecting the test sample solution to liquid chromatrography with a mobile phase including at least a first and second eluting solvent; and performing a mass spectrometry after the step of subjecting. The quality and safety ofproducts can be determined and wild-typeandderivates may be differentiated via the ratio and/or presence of certain sphingolipids especially suitable as markers.

Methods of identifying and quantifying sphingolipids

A method of isolating at least one phenanthroindolizidine alkaloid, in particular with HIF-1 inhibitory activity, fromis used to isolate and obtain for example about 22 phenanthroindolizidine alkaloids, including at least 11 new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional HIF-1 inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid to the subject.

Growing community of inventors

Taipa, Macao

Jing-Rong Wang